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Background: Chewing gum may stimulate gastrointestinal motility, with beneficial effects on post-
operative ileus suggested in small studies. The primary aim of this trial was to determine whether chewing
gum reduces length of hospital stay (LOS) after colorectal resection. Secondary aims included examining
bowel habit symptoms, complications and healthcare costs.
Methods: This clinical trial allocated patients randomly to standard postoperative care with or without
chewing gum (sugar-free gum for at least 10min, four times per day on days 1–5) in five UK hospitals.
The primary outcome was LOS. Cox regression was used to calculate hazard ratios for LOS.
Results: Data from 402 of 412 patients, of whom 199 (49⋅5 per cent) were allocated to chewing gum,
were available for analysis. Some 40 per cent of patients in both groups had laparoscopic surgery, and all
study sites used enhanced recovery programmes. Median (i.q.r.) LOS was 7 (5–11) days in both groups
(P= 0⋅962); the hazard ratio for use of gum was 0⋅94 (95 per cent c.i. 0⋅77 to 1⋅15; P = 0⋅557). Participants
allocated to gum had worse quality of life, measured using the EuroQoL 5D-3L, than controls at 6 and 12
weeks after operation (but not on day 4). They also had more complications graded III or above according
to the Dindo–Demartines–Clavien classification (16 versus 6 in the group that received standard care)
and deaths (11 versus 0), but none was classed as related to gum. No other differences were observed.
Conclusion: Chewing gum did not alter the return of bowel function or LOS after colorectal resection.
Registration number: ISRCTN55784442 (http://www.controlled-trials.com).
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Introduction
Ileus is a clinical state characterized by nausea, vomiting,
abdominal distension and an inability to pass stools/flatus.
It can delay postoperative recovery, leading to an increase
in length of hospital stay (LOS) and healthcare costs1,2.
The aetiology of ileus is multifactorial, but it may be
reduced with minimally invasive surgery, avoidance of
certain anaesthetic drugs and opiates, the use of regional
anaesthetic blocks, early postoperative mobilization, and
the use of prokinetic medication1–5. Early postoperative
feeding improves clinical outcomes after surgery, but the
risk of vomiting is increased6. Recommendations for early
postoperative feeding are included in enhanced recovery
programmes, which have been shown to reduce LOS by
2–3 days7–9.
Chewing gum is a type of sham feeding, and may reduce
ileus without increasing the risk of vomiting. Potential
mechanisms of action include the promotion of intestinal
motility via cephalovagal stimulation and the secretion
of various gastrointestinal hormones, saliva and pancre-
atic juice10. It has also been suggested that the hexitols
in sugar-free gum may play a role in resolving ileus
through their osmotic effects11. Randomized clinical trials
(RCTs), primarily in patients undergoing gastrointesti-
nal surgery, but also in caesarean section or cystectomy,
have investigated the effects of chewing gum on recovery.
Meta-analyses12–18 of these RCTs have generally shown
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that patients who chew gum after surgery have earlier
return of intestinal function (earlier passage of flatus and
stool) than those receiving standard postoperative manage-
ment. In addition, some12,15,17,18, although not all13,14,16,
reported a shorter LOS with chewing gum. Sample sizes of
RCTs in patients undergoing colorectal surgery have been
relatively small, ranging from 19 to 16818. The aim of the
present study was to look at the effects of chewing gum on
postoperative recovery by conducting an adequately pow-
ered RCT of postoperative chewing gum versus standard
care in patients after elective colorectal resection.
Methods
Participants were recruited from five hospitals in the UK
(Bristol Royal Infirmary, Derriford Hospital Plymouth,
Yeovil District Hospital, Torbay Hospital and Queen’s
Medical Centre Nottingham) between October 2010 and
April 2013. Patients scheduled for an elective colorectal
resection owing to colorectal neoplasia (invasive cancer
or dysplasia), ulcerative colitis or diverticular disease were
identified and asked to participate in the study. Potential
participants were approached by clinical and research staff
at their surgical outpatient appointment or at a preop-
erative assessment clinic. Patients were ineligible if they
were aged less than 18 years, had Crohn’s disease, were
operated on as an emergency, were pregnant or lactating,
were participating in another study that could undermine
the scientific basis of the present trial, or were deemed
unsuitable (for example, were incapable of providing ade-
quate responses/information or consent to participate in
the trial).
The trial was performed in accordance with the Dec-
laration of Helsinki, and the ethical principles of the
International Conference on Harmonization – Good
Clinical Practice. All study procedures were approved by
the National Research Ethics Service Committee South
West (REC reference number 09/H0106/37), and all study
participants provided written informed consent. The trial
is registered in the ISRCTN registry (ISRCTN55784442).
Randomization
After written informed consent had been obtained,
research staff used a computer-based tool created within
Microsoft® Access (Microsoft, Seattle, Washington, USA)
to allocate participants randomly on a 1 : 1 basis to either
standard care plus chewing gum or standard care alone.
Encryption concealed allocation until the patient’s details
had been logged. Random block sizes of two, four or six
were used, and randomization was stratified by hospital
site and within sites by disease type (colorectal neoplasia,
ulcerative colitis and diverticular disease).
Intervention
Participants allocated to chewing gum were asked to chew
a stick of commercially available sugar-free gum (Wrigley’s
5; WmWrigley Jr, Plymouth, UK) for at least 10 min, four
times a day for 5 consecutive days (or until discharge, if
less than 5 days) from the first postoperative morning. The
approximate cost per patient for a 5-day course of gum was
€1⋅61. Chewing gum was dispensed to participants by ward
staff at each of the four drug rounds per day. Participants
in the control group were asked not to chew gum during
their hospital stay. No other alterations to perioperative
care were made.
Acceptability and compliance
Acceptability of chewing gum was assessed via a brief
interview with participants in the chewing gum arm after
at least 1 complete day after operation. They were asked
how they felt about chewing gum and whether they had any
problems or difficulties chewing the gum. Compliance was
assessed by asking participants to record when, and for how
long, they chewed each piece of gum across all potential
chewing occasions (taking into account whether discharge
was before day 5). Participants in the standard care arm
were asked at the time of discharge if they had chewed gum
during their hospital stay, and if so when they had done so.
Blinding
The surgical nursing and medical team were blinded to
treatment arm at the time of the operation. Members of
the research team responsible for data collection were not
blinded to treatment allocation as data on, for example,
acceptability of gum were collected from study partici-
pants. As in other trials, given the nature of the intervention
and the lack of a suitable placebo it was not possible to
blind study participants to the treatment allocation. Due
consideration was given to blinding the surgical team
(those involved in determining suitability for discharge)
to the treatment allocation after surgery, such as using
empty boxes of ‘gum’ for control participants. However,
all solutions were deemed impractical or impossible owing
to the nature of the intervention and the need for labels
within drug charts for dispensing gum. Nonetheless, by
dispensing the chewing gum from the drugs trolley there
were no open chewing gum boxes for the surgical team to
see. Furthermore, patients and staff were instructed not to
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tell the surgical team which arm of the study they were in,
and those in the chewing gum arm were asked to discard
the wrapper straight away. The statistician was blinded
to the treatment allocation during cleaning and recoding of
the data, and the initial version of the main analyses (up to
the point of submission of the final report to funders).
Data collection
Data were collected from several sources including inter-
views, questionnaires, and chewing gum log books com-
pleted by study participants. Baseline data were collected
before surgery, and other data were collected from partic-
ipants on days 1–5, and at 6 and 12 weeks after operation.
In addition, study personnel extracted data from charts,
medical notes and electronic records where available.
Outcome measures
Results for the primary outcome (LOS) and the follow-
ing selected secondary outcomes (chosen based on other
reported studies or outcomes that were deemed relevant)
are reported here: passage of first bowel movement, pas-
sage of first flatus, and first day of auscultated bowel sounds;
patient-reported abdominal pain, nausea, vomiting, solid
food consumption and tolerance, and quality of life; and
clinical complications and death. LOS was calculated as
the number of days from the date of operation to the
date of discharge, transfer or death. Data used to generate
LOS were double-entered and any discrepancies rectified
by checking the report form or with study sites to verify
dates. Participant-reported data for bowel movement, pas-
sage of flatus and vomiting were obtained from participant
questionnaires on each of days 1–5 after operation. The
first postoperative day on which a bowel movement or fla-
tus was passed, and the presence or absence of vomiting on
day 2 after surgery, were used in analyses. Medical records
were used to determine the day (up to day 5) on which
bowel sounds were first heard, and the first postoperative
day on which they were heard was used in analyses.
The extent of abdominal pain and nausea was reported
by study participants on each of days 1–5 using a visual
analogue scale, where 0 per cent indicated no pain or no
sickness at all, and 100 per cent a lot of pain or very sick.
Data are presented for day 2 after operation. Dietary intake
on each of days 1–5 was assessed by asking study partici-
pants to circle the amount (none; about a quarter; about
a half; about three-quarters; all) of each meal (breakfast,
lunch and dinner) that they ate. The first postoperative day
on which solid food was consumed or tolerated (defined as
the consumption of at least half of 3 meals in a day without
vomiting) was used in analyses.
Quality of life was assessed using the EuroQol (EQ)
5D-3L questionnaire (EuroQol Group, Rotterdam, The
Netherlands) at baseline, day 4, and 6 and 12 weeks after
operation. The EQ-5D-3L™ summarizes health on a sin-
gle index anchored at 1 (best health) and 0 (worst health)19.
Descriptive information reported on adverse event
forms on days 1–5 after surgery was used to classify
events according to the Dindo–Demartines–Clavien
classification20. Adverse events were grouped into the
following categories: ileus/nausea/vomiting (data on vom-
iting as a clinical complication within this category was
taken from adverse event forms rather than using data
from participant-completed questionnaires), pneumonia,
anastomotic leak, wound infection, other infection, bleed-
ing, intra-abdominal collection, bowel obstruction and
death. The number of individuals per treatment group
who experienced an adverse event of at least grade III was
analysed. In addition, the number of individuals per treat-
ment group who experienced each of the adverse events
listed above, as well as the total number of individuals
per treatment group who experienced an adverse event
(irrespective of its nature), was analysed.
Power calculation and sample size
When the trial was designed, data from one study21 in
a UK population were available for estimating power for
the primary outcome (LOS), and additional data from a
systematic review12 were available for selected secondary
outcomes (time to first flatus and bowel movement). With
a sample size of 400 (approximately 200 per treatment
group), and using a two-group Student’s t test and 5
per cent two-sided significance, the estimated power for
detecting a mean difference of 1⋅5 days (s.d. 5 days) in LOS
between treatment groups was 84 per cent. The estimated
power for detecting a difference of 1 day between treatment
groups for time to first flatus (s.d. 18⋅5 h) and time to first
bowel movement (s.d. 34⋅4 h) was greater than 99 per cent.
Statistical analysis
Preoperative characteristics by treatment group were
tabulated using mean(s.d.) for normally distributed data,
median (i.q.r.) for non-normally distributed data, and
counts with percentages for categorical data. Data for LOS
were skewed, with one participant having a hospital stay
of 230 days. For LOS, Cox regression was used to test for
equality of survival curves between treatment arms, and to
calculate hazard ratios and 95 per cent confidence intervals
(c.i.); Schoenfeld residuals were used to test the propor-
tional hazards assumption. Discharges appeared as events,
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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and deaths and transfers to other hospitals as censored
observations. As a sensitivity analysis, deaths that occurred
before discharge from hospital were considered to be a
competing risk within a competing-risks regression model.
Secondary outcomes were assessed using Student’s t
test for normally distributed continuous variables, Mann–
WhitneyU test for continuous variables with a non-normal
distribution and χ2 test for categorical variables. Data were
analysed using Stata® release 13 (StataCorp, College Sta-
tion, Texas, USA).
Economic evaluation
The mean healthcare cost and quality-adjusted life-years
(QALYs) per patient in each arm of the study up to
12 weeks’ follow-up were estimated. Information on
initial hospital stay and readmissions were extracted from
the hospital records. Other service use (such as general
practitioner visits and community care) was collected
from participant-completed questionnaires at 6 and 12
weeks. Unit costs were estimated from publicly available
sources22–24 and the local hospital finance department.
UK costs were converted to euros using 2014 exchange
rates (£1= €1⋅19). QALYs were estimated based on
EQ-5D-3L™ responses at baseline, 4 days, 6 and 12 weeks.
Cost-effectiveness was summarized using the net monetary
benefit statistic, assuming that the health service is able to
pay £20 000 (approximately €23 700) per QALY gained25.
Results
A total of 412 patients were recruited between October
2010 and April 2013 (Fig. 1); follow-up of the last partici-
pant was on 16 August 2013. Ten patients were withdrawn
by investigators and not included in the analyses. Partici-
pant characteristics and baseline measures are shown in
Table 1. Overall, there were slightly moremen than women,
most participants reported that they were Caucasian, and
almost all had surgery for treatment of cancer. The trial
arms were comparable across most demographic and clini-
cal measures, although a slightly higher proportion of par-
ticipants in the chewing gum arm had a stoma formed
(36⋅9 versus 31⋅2 per cent).
Chewing gum
The majority of patients in the chewing gum arm (135;
77⋅1 per cent of those with available data) reported that
Assessed for eligibility n = 745
Excluded n = 333
 Did not meet protocol inclusion criteria n = 161
 Declined to participate n = 132
 Missed/unable to contact/not enough time to consent n = 29
 Other/unknown n = 11
Randomized n = 412
Allocated to intervention n = 204
 Withdrawn by investigators before treatment began n = 5*
 Chewed gum n = 176†
 Did not chew gum or data not available n = 23‡
Allocated to standard care n = 208
 Withdrawn by investigators before treatment began n = 5*
 Received usual care n = 185
 Did not receive usual care n = 1§
 Reported chewing gum n = 17¶
Lost to follow-up for primary outcome n = 0 Lost to follow-up for primary outcome n = 0
Analysed for primary outcome n = 199
 Excluded from analysis n = 0
Analysed for primary outcome n = 203
 Excluded from analysis n = 0
Fig. 1 CONSORT diagram for the trial. *Did not undergo colorectal resection (7 patients), participating in another trial (1), had been
operated on as an emergency (1), or deemed unsuitable based on intraoperative problems and subsequent intensive therapy unit
admission (1). †On at least one occasion according to chewing gum log. ‡Chewing gum log showed that: gum had been received but
there was no information on whether or not it had been chewed (4); gum had not been received (4, 1 of whom had not been given gum
in error); no information on whether or not gum had been received or chewed (15). §Chewing gum provided in error. ¶Questionnaire
on use of gum in standard care group indicated that gum had been chewed at least once during days 1–5 after surgery
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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(% of patients in group)
Standard care
(% of patients in group)
Age (years)† 199 of 402 (49⋅5) 65⋅5(14⋅1) 66⋅9(11⋅6)
Sex
M 111 of 230 (48⋅3) 55⋅8 58⋅6
F 88 of 172 (51⋅2) 44⋅2 41⋅4
Ethnicity
Caucasian 194 of 385 (50⋅4) 98⋅5 96⋅5
Black 0 of 5 (0) 0 2⋅5
Other 3 of 5 (60) 1⋅5 1⋅0
Level of education‡
O-level, GCSE, school certificate or less 127 of 254 (50⋅0) 67⋅6 67⋅6
A-level 24 of 48 (50) 12⋅8 12⋅8
Degree 37 of 74 (50) 19⋅7 19⋅7
Smoking status
Current smoker 22 of 35 (63) 11⋅2 6⋅6
Former smoker 100 of 210 (47⋅6) 51⋅0 56⋅1
Never smoked 74 of 147 (50⋅3) 37⋅8 37⋅2
Body mass index (kg/m2)† 199 of 400 (49⋅8) 27⋅9(5⋅4) 27⋅2(4⋅8)
EQ-5D-3 L™ quality-of-life score† 194 of 389 (49⋅9) 0⋅82(0⋅23) 0⋅84(0⋅19)
ASA fitness grade
I 28 of 49 (57) 15⋅0 11⋅1
II 117 of 244 (48⋅0) 62⋅6 66⋅8
III 42 of 84 (50) 22⋅5 22⋅1
Indication for surgery
Colorectal neoplasia 184 of 372 (49⋅5) 92⋅5 92⋅6
Diverticular disease 7 of 16 (44) 3⋅5 4⋅4
Ulcerative colitis 8 of 14 (57) 4⋅0 3⋅0
Type of surgery
Open 86 of 178 (48⋅3) 43⋅4 45⋅5
Laparoscopic 78 of 159 (49⋅1) 39⋅4 40⋅1
Laparoscopically assisted 22 of 43 (51) 11⋅1 10⋅4
Laparoscopic converted to open 12 of 20 (60) 6⋅1 4⋅0
Stoma formed§
Yes 73 of 136 (53⋅7) 36⋅9 31⋅2
No 125 of 264 (47⋅3) 63⋅1 68⋅8
Primary procedure
Total colectomy 12 of 20 (60) 6⋅1 3⋅9
Right-sided colectomy 56 of 117 (47⋅9) 28⋅4 30⋅1
Left-sided colectomy 34 of 69 (49) 17⋅3 17⋅2
Rectal resection 84 of 168 (50⋅0) 42⋅6 41⋅4
Other¶ 11 of 26 (42) 5⋅6 7⋅4
*Values in parentheses are percentages; the overall number of patients was 402 (199 in chewing gum group and 203 in standard care group), but totals
may not add up to this as there were some missing data. †Values are mean(s.d.). ‡O-level, GCSE, school certificate: national school examinations at age
16 years; A-level: national school examinations at age 18 years. §Data from day 1 after operation. ¶Includes partial resection and small bowel resection.
EQ, EuroQol; ASA, American Society of Anesthesiologists.
they were happy to chew the gum and 122 (72⋅2 per cent
of those with available data) said that they did not have any
problems or difficulties. Data from chewing gum log books
or acceptability of gum questionnaires showed that 176
participants chewed gum on at least one potential occasion,
and 23 participants either did not chew gumor no data were
available to ascertain whether they had or not (Fig. 1). For
those with available data, gum was chewed on a median
of 58 (i.q.r. 20–83) per cent of the occasions on which
it had been received, for a mean(s.d.) of 12(7) min each
time.
Seventeen participants (8⋅2 per cent) in the standard
care arm reported that they had chewed gum during their
hospital stay. Of these, one had been given trial gum in
error, two said they chewed it on the first postoperative day
and 13 reported that they chewed gum between days 2 and
5 after surgery. Data on when gum was chewed were not
available for one individual.
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Table 2 Comparison of primary outcome (length of stay) and selected secondary outcome measures between treatment groups
Overall proportion receiving gum‡ Chewing gum Standard care P#
Length of postoperative hospital stay (days) 199 of 402 (49⋅5) 7 (5–11) 7 (5–11) 0⋅962
Postoperative day bowel sounds first heard 58 of 136 (42⋅6) 2 (1–3) 2 (1–3) 0⋅619
Postoperative day of first flatus 130 of 268 (48⋅5) 2 (2–3) 2 (1–3) 0⋅586
Postoperative day of first bowel movement 159 of 310 (51⋅3) 2 (1–3) 3 (1–4) 0⋅153
Postoperative day first ate solid food 188 of 385 (48⋅8) 1 (1–2) 1 (1–2) 0⋅920
Postoperative day solid food tolerated§ 131 of 260 (50⋅4) 2 (1–3) 2 (1–3) 0⋅223
Abdominal pain score (%)¶ 154 of 324 (47⋅5) 49 (22–69) 43 (21–65) 0⋅496
Nausea score (%)¶ 156 of 327 (47⋅7) 9 (2–52) 10 (2–51) 0⋅662
Vomiting on day 2 0⋅930**
Yes 36 of 70 (51) 18⋅3† 16⋅8†
No 144 of 294 (49⋅0) 73⋅1† 74⋅3†
Not known 17 of 35 (49) 8⋅6† 8⋅9†
EQ-5D-3 L™ quality-of-life score*
Day 4 138 of 273 (50⋅5) 0⋅44(0⋅35) 0⋅50(0⋅34) 0⋅116††
6weeks 163 of 328 (49⋅7) 0⋅67(0⋅32) 0⋅76(0⋅23) 0⋅004††
12weeks 142 of 292 (48⋅6) 0⋅74(0⋅31) 0⋅80(0⋅21) 0⋅036††
Values in parentheses are median (i.q.r.) unless indicated otherwise; *values are mean(s.d.); †values are percentage of patients in group. ‡Values in
parentheses are percentages; the overall number of patients was 402 (199 in chewing gum group and 203 in standard care group), but totals may not add
up to this as there were some missing data. For gum and standard care groups, bowel sounds, flatus and bowel movement events were reported as ‘not
known’ for 92 and 80, 45 and 41, and one and two patients respectively, and data were missing on at least 1 relevant day for 49 and 45, 24 and 24, and 23
and 26 respectively; for bowel movement, event was reported as ‘no’ for 16 and 24 patients respectively. §Ate at least half of three meals in a day without
vomiting. ¶Visual analogue scale score on day 2 after surgery (0 per cent, none at all; 100 per cent, a lot of pain or very sick). #Mann–Whitney U test,
except **χ2 test and ††t test.
Table 3 Number of documented episodes of selected
complications between days 1 and 5 after surgery
Total Chewing gum Standard care P†
Suspected or confirmed
anastomotic leak
13 6 7 0⋅815
Bowel obstruction 2 1 1 –
Confirmed or suspected
wound infection
5 2 3 –
Confirmed or suspected
other infection
20 9 11 0⋅691
Vomiting*/nausea/ileus 47 19 28 0⋅197
Pneumonia 17 8 9 0⋅847
Bleeding 16 8 8 0⋅958
Intra-abdominal collection 1 1 0 –
Other 49 26 23 0⋅582
Death 3 3 0 –
*Data on vomiting taken only from adverse event forms; no
participant-reported data used. †χ2 test; no formal statistical comparison
was done when few participants experienced the complication.
Primary outcome
LOS ranged from 2 to 230 days. Median LOS in both
treatment groups was 7 (i.q.r. 5–11) days (Table 2). The
assumption of proportional hazards was met (χ2 = 0⋅03,
P= 0⋅872). The estimated coefficient for discharge in the
gum compared with standard care arm was −0⋅06 (95 per
cent c.i. –0⋅26 to 0⋅14), and the associated hazard ratio
was 0⋅94 (95 per cent c.i. 0⋅77 to 1⋅15; P= 0⋅557). Treating
deaths as a competing risk, the coefficient for discharge
in the gum compared with standard care arm was −0⋅15
(−0⋅33 to 0⋅03), and the associated sub-hazard ratio was
0⋅86 (0⋅72 to 1⋅03; P= 0⋅102).
Secondary outcomes
Bowel habit, bowel sounds and food consumption
There was a median of 2 days after operation until first
occurrence of a bowel movement, flatus and bowel sounds
among participants in both treatment groups (with the
exception of day 3 for bowel movement in the standard care
arm); there were no differences between groups (Table 2).
Nor were there any differences between groups in median
reported day of first consumption of solid food and tolera-
tion of solid food, which were days 1 and 2 respectively.
Abdominal pain, nausea, vomiting and quality of life
There were no differences between treatment groups in
abdominal pain and nausea on day 2 after surgery: median
scores were 49 and 9 per cent respectively for participants
in the chewing gum group, and 43 and 10 per cent in the
standard care group (Table 2). Data for all other days were
similar (data not shown). Similar numbers of participants in
both treatment groups reported having vomited on each of
days 1–5 after operation; data for day 2 are shown inTable 2.
There was no difference in quality of life between the
treatment groups, assessed by means of the EQ-5D-3L™,
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Table 4 Total and incremental costs and quality-adjusted life-years
Overall proportion receiving gum* Chewing gum† Standard care† Difference‡ P
Primary/community costs (€) 151 of 326 (46⋅3) 239(264) 210(242) 28 (−27, 83) 0⋅316
Hospital costs (€) 199 of 402 (49⋅5) 3773(8934) 3177(5391) 596 (−848, 2039) 0⋅418
Total health service costs (€) 151 of 326 (46⋅3) 3131(3117) 2806(2598) 325 (−298, 948) 0⋅306
QALYs 90 of 193 (46⋅6) 0⋅149(0⋅059) 0⋅164(0⋅043) −0⋅012§ (−0⋅026, 0⋅002) 0⋅097
Net monetary benefit (€) 77 of 178 (43⋅3) 874(2952) 1048(3234) −173 (−1103, 757) 0⋅713
*Values in parentheses are percentages; the overall number of patients was 402 (199 in chewing gum group and 203 in standard care group), but totals
may not add up to this as there were some missing data. †Values are mean(s.d.); ‡values in parentheses are 95 per cent c.i. §Mean difference in
quality-adjusted life-years (QALYs) after adjustment for baseline EuroQol 5D-3L™ score26.
on day 4 after operation, but scores at 6 and 12 weeks were
worse in the chewing gum group (Table 2).
Complications
During days 1–5 after operation, 22 individuals (16 gum,
6 standard care) had an adverse event of at least grade III
(P= 0⋅027), but all were classed as not related, or unlikely
to be related, to the intervention. Considering potentially
relevant complications that had been grouped using data
reported on adverse event forms, there were no differ-
ences between treatment groups in the number of doc-
umented episodes within each category (Table 3). Over-
all, 57 and 60 people in the gum and control groups
respectively experienced at least one of the complications
listed in Table 3 (P= 0⋅840). One complication in the chew-
ing gum group was considered possibly related to the
intervention (described as ‘postop ileus’ and included in
the vomiting/nausea/ileus category), but all others were
classed as not related, or unlikely to be related, to the
intervention.
Eleven patients died during the study, all in the chewing
gum arm. Nine died before the 12-week follow-up (2
after discharge), and two died after the 12-week follow-up
but before discharge from hospital. Detailed information
on cause of death for ten of the 11 participants (medical
records were not accessible for 1 individual) was reviewed
by clinicians at each study site. Chewing gum was not
considered related to the causes of death.
Economic evaluation
Mean hospital costs were slightly higher (by €596) for
patients in the chewing gum group, but the difference
was explained almost entirely by one patient who spent
a long period in the intensive care unit (Table 4). Pri-
mary and community care use was also similar between
the two arms of the trial. There was no difference in
mean QALYs between the intervention and standard care
arms (Table 4). Patients in the gum group had a lower net
benefit (mean difference –€173, 95 per cent c.i. –€1103
to 757), indicating that gum chewing is unlikely to be
cost-effective.
Discussion
There were no differences in LOS or in most secondary
outcomes between patients randomized to receive post-
operative chewing gum and those allocated to standard
care. There was a suggestion of more severe complications
in the chewing gum group, but none was classed as related
to chewing gum. There was no evidence to suggest sub-
stantial effects of chewing gum on overall costs. Chewing
gum after colorectal surgery is unlikely to be cost-effective.
Systematic reviews and meta analyses12,15,17,18 of studies
in specific surgery types (such as colorectal) or abdominal
surgery in general have shown positive effects of chew-
ing gum on outcomes such as return of bowel function
and possibly also LOS, but issues such as heterogeneity
and insufficient data on which to base conclusions have
been highlighted15,17,18. The findings of the present trial
are in agreement with a recent, relatively large trial (168
patients)27 of postoperative chewing gum in patients under-
going colorectal resection, which reported no effects of
chewing gum on return of bowel function, LOS and other
secondary outcomes, similar to those reported here. A
potential reason for the lack of an effect of chewing gum
in this trial is that all study sites routinely use enhanced
recovery programmes that include early feeding. This may
have negated any potential effects of chewing gum in the
trial.
Few previous studies have assessed or reported on com-
pliance with chewing gum regimens, which was very good
in this trial. The gum was well tolerated by participants,
with most reporting that they were happy to chew it.
Although a large proportion of the participants did not
achieve 100 per cent compliance, this was not surprising
given that they had all undergone major colorectal surgery.
An unexpected finding in this trial was that all deaths
during follow-up were among participants in the chewing
gum arm. However, a detailed investigation of the causes of
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
on behalf of BJS Society Ltd.
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death did not provide any information to suggest that the
deaths were related to chewing gum. Furthermore, con-
sidering all potentially relevant complications, there were
no differences between treatment groups, and only one
(described as ‘postop ileus’) was considered possibly related
to the intervention. Most other outcomes reported here
were not substantially affected by treatment, or adversely
affected by chewing gum. The results taken together sug-
gest that the observed excess mortality in the intervention
arm is a chance finding.
This study has some limitations. Given the nature of
the intervention (chewing gum versus standard care) it
was either not possible or very difficult to blind study
participants or study personnel/ward staff. This limitation
is common to most other similar studies17,18. The lack
of differences between treatment groups, especially in
regard to outcomes unlikely to be influenced by know-
ledge of treatment allocation (such as anastomotic leak),
combined with the fact that the findings of this trial are
similar to those reported in other (albeit smaller) studies18,
provides some reassurance that the findings may not have
been subject to such bias. It is possible that knowledge
of the treatment allocation may have altered participant
responses, but the only difference between groups was
a worse quality of life at 6 and 12 weeks in the chewing
gum arm. A few individuals (less than 2⋅5 per cent) were
withdrawn by investigators after randomization as they no
longer met the protocol inclusion criteria, but the same
number of patients was withdrawn from both treatment
groups. The findings may not be generalizable to other
populations, patients with other medical conditions and
patients undergoing different procedures. The primary
outcome was LOS, but a more appropriate primary out-
come may have been a marker of postoperative ileus or
clinical complications, as these would have been less influ-
enced by local policies concerning discharge from hospital.
Finally, relatively large amounts of data were missing for
some of the secondary outcomes (such as bowel sounds),
which may limit the interpretation of the findings.
A recent formal systematic review18 of the available
evidence in this field included preliminary data from this
trial. The overall findings of the review (which included all
abdominal surgery) showed that chewing gum was associ-
ated with an earlier return of bowel function and a reduc-
tion in LOS of 0⋅7 (95 per cent c.i. –0⋅8 to −0⋅5) days,
but there was little effect on complications18. This mod-
est reduction in LOS was, however, based on poor-quality
evidence and the clinical importance of chewing gum may
be diminished in the context of enhanced recovery pro-
grammes. Nonetheless, no serious adverse events were
attributed to chewing gum. This suggests that chewing
gum can be neither clearly recommended nor prohibited
as a gastrointestinal stimulant.
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